"instanceType","label","id","description","name","uuid:ID","rationale"
"StudyDesign","","StudyDesign_1","The main design for the study","Study Design 1","ead96656-65f4-41a5-b8d6-16e966548fb6","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
